Tirzepatide (Mounjaro) is a dual agonist targeting both GLP-1 and GIP receptors, which tends to produce greater weight loss
Gather the right records
The Cost Challenge: Understanding and Managing GLP-1 Costs Despite their effectiveness, GLP-1s are among the most expensive weight loss interventions, with costs ranging from $1,000 to $1,500 per month per patient
A subset of patients with severe obesity who kept taking retatrutide in a study extension continued to slim down, losing up to an average of 85 pounds, or 30% of their body weight, at two years, the company said in a statement detailing the Phase 3 trial results
Additional Considerations Common side effects seen with Wegovy may include: Nausea or vomiting Diarrhea or constipation Abdominal pain Headache Tiredness Contact your healthcare provider if you have any of the following side effects: Abdominal pain, nausea, or vomiting that does not go away
When incorporating impacts from the various indications of incretin-based therapies, care should be taken to avoid double-counting